Score Overview
Arrowhead Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 87M to $ 829M and net income went from -$ 84M to -$ 1M. Revenue increased in 2 of those 5 years; net income in 1.
Across Arrowhead Pharmaceuticals Inc's full reported history, from 1997 to 2025, revenue grew from $ 76.59K to $ 829M and net income went from -$ 854.53K to -$ 1M. Revenue increased in 44% of the years measured; net income in 38%.
Arrowhead Pharmaceuticals Inc currently holds a 20-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 87.25 | — |
1 Year2025-08-12 | $ 17.80 | 390.17% |
5 Years2021-08-12 | $ 59.79 | 45.93% |
10 Years2016-08-12 | $ 5.96 | 14x |
20 Years2006-08-11 | $ 48.20 | 81.02% |
30 Years1996-08-01 | $ 111.72 | -21.90% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-01 |
|---|---|---|---|---|---|---|
| Price | $ 87.25 | $ 17.80 | $ 59.79 | $ 5.96 | $ 48.20 | $ 111.72 |
| Return | — | 390.17% | 45.93% | 14x | 81.02% | -21.90% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 669M | -$ 319M | $ 1.60B |
| 2025 | $ 829M | -$ 1M | $ 919M |
| 2024 | $ 3M | -$ 599M | $ 680M |
| 2023 | $ 240M | -$ 205M | $ 403M |
| 2022 | $ 243M | -$ 176M | $ 376M |
| 2021 | $ 138M | -$ 140M | $ 367M |
| 2020 | $ 87M | -$ 84M | $ 315M |
| 2019 | $ 168M | $ 67M | $ 258M |
| 2018 | $ 16M | -$ 54M | $ 76M |
| 2017 | $ 31M | -$ 34M | $ 65M |
| 2016 | $ 158.33K | -$ 81M | $ 85M |
| 2015 | $ 382K | -$ 91M | $ 98M |
| 2014 | $ 175K | -$ 58M | $ 154M |
| 2013 | $ 290.27K | -$ 31M | $ 28M |
| 2012 | $ 146.88K | -$ 21M | $ 3M |
| 2011 | $ 296.14K | -$ 3M | $ 8M |
| 2010 | $ 620.1K | -$ 5M | $ 6M |
| 2009 | $ 3M | -$ 19M | $ 2M |
| 2008 | $ 1M | -$ 27M | $ 10M |
| 2007 | $ 1M | -$ 29M | $ 24M |
| 2006 | $ 595.46K | -$ 18M | $ 28M |
| 2005 | $ 590.68K | -$ 6M | $ 22M |
| 2004 | $ 196.31K | -$ 2M | $ 9M |
| 2003 | -$ 95.24K | $ 1M | |
| 2002 | $ 2.27K | -$ 246.21K | $ 18.49K |
| 2001 | $ 9.31K | -$ 185.82K | $ 271.00 |
| 2000 | $ 24.88K | -$ 137.55K | $ 1.95K |
| 1999 | $ 37K | $ 593K | $ 124.00 |
| 1998 | $ 60.38K | -$ 165.03K | $ 1.02K |
| 1997 | $ 76.59K | -$ 854.53K | $ 1.17K |
Explore beyond ARWR
You're looking at Arrowhead Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
